JPRN-UMIN000012054招募中1 期
Phase I study of S-1, irinotecan plus oxaliplatin combination therapy (S-IROX) for advanced pancreatic cancer - Phase I study of S-IROX for advanced pancreatic cancer
适应症
试验速览
- 阶段
- 1 期
- 状态
- 招募中
- 入组人数
- 24
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 20years-old 至 75years-old（—）
- 性别
- All
入选标准
- 未提供
排除标准
- •1) Grade 2 or greater peripheral neuropathy 2) Having UGT1A1*6/*6, UGT1A1*28/*28, or UGT1A1*6/*28 gene 3) Moderate ascites 4)Intestinal pneumonitis or pulmonary fibrosis 5) Uncontrollable diarrhea 6) Serious complications (organ failure, uncontrolled diabetes mellitus, active infection, ulcer, ileus, mental disorders, or central nervous system disorders) 8) Active double cancer 9) Pregnancy 10)Inappropriate for this study judged by the attending physician
研究者
相似试验
招募中
不适用
Phase I/II study of S-1, irinotecan plus oxaliplatin combination therapy (SOXIRI) for advanced pancreatic cancer(KANAPS 06 study)advanced pancreatic cancerJPRN-UMIN000014339KANAPS(Kansai and Nara Pancreatobiliary Study group)53
已完成
不适用
Phase I study of irinotecan, S-1 and oxaliplatin in combination with radiation therapy in patients with advanced rectal canceradvanced rectal cancerJPRN-UMIN000017674Department of Gastrointestinal and Pediatric Surgery, Division of Reparative Medicine, Institute of Life Sciences, Mie University Graduate School of Medicine12
已完成
2 期
A Phase II Study of Irinotecan, Oxaliplatin, Plus TS-1 in Untreated Metastatic Gastric CancerStomach NeoplasmsNCT00512681National Cancer Center, Korea44
进行中（未招募）
2 期
Phase2 trial of oxaliplatin, irinotecan and S-1 (OX-IRIS) as first line chemotherapy for unresectable pancreatic cancerpancreatic cancerJPRN-jRCTs011190008Komatsu Yoshito40
Unknown
2 期
Phase II Study of Irinotecan,Oxaliplatin Plus TS-1 in Untreated Metastatic Colorectal CancerColorecal NeoplasmsSecondaryNCT00506571National Cancer Center, Korea42